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Background: Increased antibiotic resistance against Staphylococcus aureus and low penetration into bone requires
regimen optimization of available drugs.
Methods: We evaluate pharmoacokinetic and pharmacodynamic parameters (PK/PD) as well as in vivo interactions
of continuous flucloxacillin 12 g/d administration combined with high dose oral rifampicin 600 mg bid in the
serum of 15 adult patients with bone and soft tissue infections. We use the patient’s own serum directed against
his own isolated S. aureus strain to reproduce in vivo conditions as closely as possible.
Results: The continuous flucloxacillin infusion constantly generated plasma free drug levels largely exceeding the
serum minimal inhibitory concentrations (mean 74-fold). Combination with rifampicin significantly increased flucloxacillin
levels by 44.5%. Such an increase following rifampicin introduction was documented in 10/15 patients, whereas a
decrease was observed in 1/15 patients. Finally, all infections were cured and the combination was well tolerated.
Conclusions: In this in vivo methodological pilot study among adult patients with orthopaedic infections due to S.
aureus, we describe a new method and reveal substantial but inconsistent interactions between flucloxacillin and
rifampicin, of which the clinical significance remains unclear.
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Staphylococcus aureus is one of the most prevalent patho-
gen in bone and soft-tissue infections associated with and
without foreign material. When implants are involved, S.
aureus develops a biofilm in which most antimicrobial
agents reveal inability to kill non-growing bacteria. The
only clinically available exception is rifampicin/rifampin
(Uçkay et al. 2009). Since rifampicin monotherapy may* Correspondence: Ilker.Uckay@hcuge.ch
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in any medium, provided the original work is plead to rapid emergence of rifampicin-resistant S. aureus,
this drug should always be combined with other systemic
antibiotics (Widmer et al. 1992; Zavasky and Sande 1998).
Continuous intravenous administration of a β-lactam
antibiotics has been suggested more beneficial than
intermittent drug use (Boselli et al. 2008; Drusano 2004;
Landersdorfer et al. 2007). Flucloxacillin is a synthetic
penicillinase-resistant penicillin similar to oxacillin or
methicillin; with excellent anti-staphylococcal activity. For
severe bone and soft tissue infections due to S. aureus,
whether associated with orthopaedic implants or not, only
limited data is currently available for flucloxacillin in
continuous infusion alone (Howden and Richards 2001;
Hackbarth et al. 1986; Leder et al. 1999) or in combinationan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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microbial drugs against S. aureus by the industry is limited
(Jugun et al. 2013). Therefore, new pharmacokinetic and
pharmacodynamic (PK/PD) studies in vivo are required to
optimize the potency of today’s available antimicrobial
regimens (Le and Bayer 2003; Czekaj et al. 2011). In this
methodological and pilot study, we prospectively investi-
gate activity parameters of a combined oral rifampicin and
continuous flucloxacillin regimen in 15 adult hospitalized
patients. Methodologically speaking, we use the patient’s
own serum directed against his own isolated S. aureus
strain to reproduce in vivo conditions as closely as pos-
sible. This method may be clinically more relevant than
in vitro studies on synergism/antagonism. Of note, this
study wasn’t designed to measure clinical outcome, and is
focused on pharmocologic parameters in vivo only.
Methods
Subjects and treatment
Fifteen adult patients hospitalized for acute bone and
soft tissue infections due to S. aureus were prospectively
included in this methodological pilot study. Informed pa-
tient consent was obtained, in accordance with local institu-
tion policy. All subjects had microbiological identification
of S. aureus in more than two concordant intraoperative
bacterial cultures and a normal hepatic and renal function
(creatinin-clearance > 50 ml/min). Exclusion criteria were
polymicrobial infections, co-medication with any drug
known for significant interaction with rifampicin, patients
with allergy or intolerance to flucloxacillin and/or rifampi-
cin, and hepatitis (serum transaminase levels >3× upper
normal limit or cirrhosis CHILD B or C).
All patients were antibiotic-naïve prior to flucloxacillin/
rifampicin therapy being started. Continuous intravenous
flucloxacillin 12 g/d without loading dose was initiated as
soon as S. aureus infection was suspected on the basis of a
positive Gram-staining while awaiting culture pathogen
identification. After 72 h, flucloxacillin was considered at
steady state, because of its serum half-life of 0.75-1.5 h.
Oral rifampicin 600 mg bid was added after culture con-
firmation and kept throughout the therapy. Duration of
combined treatment with flucloxacillin and rifampicin
followed current recommendations (Trampuz and Zimmerli
2006; Bernard et al. 2010). Surgery was performed accord-
ing to standard of care. Staphylococci species were charac-
terized by slidex agglutination (Pastorex®, BIO-RAD) and
the ID32 Staphylococcus Gallery (bioMérieux, Marcy L’Etoile,
France) and according to Clinical and Laboratory Standard
Institute guidelines (CLSI 2008).
Pharmacologic analyses
Serum was collected at three predetermined time points.
A: 72 h after initiation of flucloxacillin; B: at 48 h after
rifampicin treatment onset but 30 minutes before thefifth dose was delivered (rifampicin trough level); C:
1 hour after fifth rifampicin dose (rifampicin peak level).
At each time point, serum flucloxacillin (A,B,C) and ri-
fampicin (B,C) concentrations were assessed using high
liquid pressure chromatography technique. A specific and
automatable assay was developed for simultaneous flu-
cloxacillin and rifampicin quantification in human plasma.
A Prontosil C18 AQ+ 150 × 4.6 mm column was used for
chromatographic separation. Voriconazole was used as in-
ternal standard (IS). UV detection was set at three wave-
lengths: 220 nm for flucloxacillin, 340 nm for rifampicin
and 260 nm for IS. Retention times were 3.8 min, 6 min.
and 7 min. for flucloxacillin, rifampicin and IS respect-
ively. Rifampicin and flucloxacillin were extracted from
plasma and mixed with IS solution, an orthoboric acid
pH 3.5-solution and an ascorbic acid solution to prevent
rifampicin oxidation. Limits of quantification and detec-
tion were 0.25-0.1 μg/ml for flucloxacillin, and 0.1-
0.03 μg/ml for rifampicin, respectively. Data’s validation
for accuracy in intra and inter-day precision were good.
Coefficient of variation for flucloxacillin was between
3.43% and 8.58% and accuracy between 94.2% and
103.7%. For rifampicin, the corresponding numbers
were between 1.07% and 7.54% and between 96.0% and
106.4%, respectively.
Flucloxacillin steady-state concentrations were mea-
sured before 600 mg rifampicin was initiated (time point
A) and at two time points afterwards (B and C). The ob-
served minimum and maximum concentrations of rifam-
picin were assumed to be at time point B (trough level)
and C (peak level 1 h after), respectively. Steady-state
concentration-time data for flucloxacillin were analyzed
with a standard pharmacokinetic method by using Kinetica™
software (Version 4.4, San Diego, USA). Steady-state
concentration-time data for rifampicin were analyzed by
population pharmacokinetic methods by using NPEM™
software (Los Angeles, USA).Serum minimal inhibitory concentration (SMIC) and
bactericidal concentration (SMBC)
For every patient, SMIC was determined at every time
point using the microdilution method. Briefly, patient’s
serum was incubated for 24 h at 37°C after being added
10E6 colony forming units of S. aureus per serum milli-
liter. The S. aureus used was the same isolate that was
isolated from the patient in question. SMIC was defined
as the highest dilution that did not exhibit visible growth.
Tests were performed in accordance with National Com-
mittee for Clinical Laboratory Standards recommendations
(NCCLS 1999). The SMBC was defined as the concentra-
tion at which growth plates displayed killing ≥ 99.9% of the
inoculum. All experiments for SMIC and SMBC were con-
ducted in triplicate.
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Group comparisons were performed using the Wilcoxon-
ranksum-test or the Kruskal-Wallis-test, as appropriate.
P values ≤0.05 (two-tailed) were significant. Analyses




A total of 15 patients (age, 35-75 years) with S. aureus in-
fections were enrolled according to inclusion/exclusion
criteria: 4 cellulitis with abscesses, 4 native joint infections,
3 infected orthopaedic implants, 2 spondylodiscitis, 2 bur-
sitis and 1 case of pin-track infection with acute osteo-
myelitis. One patient had both cellulitis and osteomyelitis.
Two episodes were bacteremic. Surgery was performed in
all patients: drainage (8×), debridement (3×), bursectomy
(2×), one-stage prosthesis exchange (1×) and pin removal
(1×). All subjects completed the study and had complete
infectious remission after the completion of therapy with
a minimum follow-up of 12 months. Duration of treat-
ment was variable according to the infection (14 to 41d,
mean 23 days). All S. aureus strains were highly sensitive
to both studied drugs. SMIC for flucloxacillin ranged be-
tween 0.25-1 μg/ml (mean 0.78 μg/ml), and SMIC forTable 1 Reciprocal serum minimal inhibitory and bactericidal
Reciprocal serum minimal inhibitory dilutions (reciprocal titer




Patient TP-A TP-B TP-C
1 32 128 256 2.5
2 256 64 256 -1
3 32 64 1024 3
4 128 1024 1024 3
5 128 128 128 0
6 512 64 128 -2.5
7 32 128 32 1
8 128 512 512 2
9 64 256 512 2.5
10 32 128 256 2.5
11 128 512 1024 2.5
12 64 512 128 2
13 128 512 512 2
14 32 128 128 2
15 256 128 256 -0.5
FOXA = Continuous intravenous flucloxacillin 12 g/d. RIF = Oral rifampin 600 mg bid
+Units are not written to spare space. Units are in μg/ml.
*Activity change expressed in dilutions. Calculated as difference between activity w
measured after RIF adjunction (time points B and C). Positive values denote increasrifampicin ranged between 0.015-0.03 μg/ml (mean
0.019 μg/ml) (CLSI 2008). Continuous flucloxacillin
generated a mean serum level of 34 μg/ml (range 19.9-
65.3). After adding rifampicin, on average flucloxacillin
concentration increased significantly by 44.6% to a mean
serum value of 45.6 μg/ml (range, 28.7-65.6) (p = 0.0008).
In contrast, a highly significant difference was docu-
mented between SMIC at time point A and C, with a
mean value increasing from 1:130 to 1:412 (p < 0.001).
Only one patient showed decreased activity after adding
rifampicin (Table 1). There was no occurrence of signifi-
cant medicamentous hepatitis with serum transami-
nases levels above the upper limit or liver insufficiency.
Discussion
We performed a methodological pilot study using the
patient’s own serum directed against his own isolated
S. aureus strain to reproduce in vivo conditions as
closely as possible. We furthermore demonstrate signifi-
cant pharmacologic interaction during simultaneous
administration of continuous 12 g per day flucloxacillin
and oral rifampicin 600 mg twice daily in 15 adult
patients with various musculoskeletal infections due to
S. aureus. Of note, our study did not demonstrate true
synergism when using this combined regimen. The titerdilutions+
)+ Reciprocal serum minimal bacterial dilutions (reciprocal titer)+







8 <2 <2 -3
<2 4 <2 1
<2 <2 1024 9
<2 32 32 5
<2 <2 16 2
<2 <2 <2 0
4 <2 <2 -2
2 <2 <2 -1
64 <2 <2 -6
8 <2 <2 -3
128 512 1024 2.5
4 <2 <2 -2
2 <2 2 -0.5
16 <2 <2 -4
64 <2 <2 -6
.
ith FOXA alone (time point A) and the mean activity in the 2 conditions
e activity, negative ones decreased activity.
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were administered simultaneously in comparison to one
drug alone. There was a wide discrepancy between in-
hibitory and bactericidal serum dilutions in the majority
of patients. This finding is inconsistent with what would
be expected for bactericidal drugs in which the SMBC is
usually within 4-fold of the SMIC.
Literature is controversial regarding synergism vs. an-
tagonism of flucloxacillin combination with rifampicin/
rifampin (Brandt et al. 1994; Hackbarth et al. 1986;
Massanari and Donta 1978; Swanberg and Tuazon 1984;
Van der Auwera and Klastersky 1983; Van der Auwera
et al. 1983, 1985; Zak et al. 1983; Zinner et al. 1981a, b).
Overall, results between different in vitro studies correlate
poorly and no single method has currently been proven
superior to another (Bliziotis et al. 2007; Perlroth et al.
2008). Therefore, we have opted to study pharmagologic
activities using the patient’s own serum directed
against his own isolated S. aureus strain to reproduce
in vivo conditions as closely as possible. Thus, our
method of testing patient’s own serum with patient’s
own S. aureus is novel to the best of our knowledge.
Most of our patients’ serum collected under combined
therapy showed enhanced antistaphylococcal flucloxa-
cillin activity when tested in vitro. Sera collected at
peak rifampicin concentration showed an increased,
unchanged or decreased effect in 10 (67%), 4 (27%) and
1 (7%) cases respectively, when compared with sera
collected before rifampicin introduction.
In conclusion, we report that in continuous infusion
with 12 g/d, serum flucloxacillin levels constantly exceeded
by several folds the MIC for S. aureus and the association
with rifampicin may further increase these serum levels.
We also demonstrate that combination of rifampicin with
a flucloxacillin may partially lead to an increased bacteri-
cidal effect, which was, however, not consistent in all pa-
tients. Our study used the patient’s own serum directed
against his own isolated S. aureus strain to reproduce
in vivo conditions as closely as possible. The method used
in the present study may be clinically more relevant than
in vitro studies on synergism/antagonism. This was a
methodological, pilot, and an in vivo pharmocologic study
and not a clinical outcome study. All 15 patients were
considered cured after a minimal follow-up of 12 months;
however, our small cohort of patients makes it impossible
to assess the clinical efficacy and relevance of our flu-
cloxacillin and rifampicin serum interaction findings.
Treatment may as well have been successful with a
combination of surgery and flucloxacillin alone, particu-
larly in the case of soft tissue infections such as cellulitis
and bursitis.Competing interests
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